|
| Status |
Public on Nov 09, 2018 |
| Title |
SPI1/PU.1 controls fibroblast polarization and tissue fibrosis |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Fibroblasts are polymorphic cells with pleiotropic roles in organ morphogenesis, tissue homeostasis and immune responses. In fibrotic diseases, fibroblasts synthesize abundant amounts of extracellular matrix which lead to scaring and organ failure. In sharp contrast, the hallmark feature of fibroblasts in arthritis is matrix degradation by the release of metalloproteinases and degrading enzymes, and subsequent tissue destruction. The mechanisms driving these functionally opposing pro-fibrotic and pro-inflammatory phenotypes of fibroblasts are enigmatic.
We have compared resting, fibrotic, and inflammatory fibroblasts; PU.1 was overexpressed in dermal fibroblasts and compared to scr-transfected controls. Fibrotic fibroblasts isolated from the skin of patients with systemic sclerosis were treated with PU.1 inhibitor and compared to untreated fibrotic fibroblasts and respective healthy controls.
Through this, we identified the transcription factor PU.1 as an essential orchestrator of the pro-fibrotic gene expression program. The interplay between transcriptional and post-transcriptional mechanisms which normally control PU.1 expression is perturbed in fibrotic diseases such as pulmonary fibrosis, systemic sclerosis, liver cirrhosis, kidney fibrosis and chronic graft-versus-host disease, resulting in upregulation of PU.1, the induction of fibrosis-associated gene sets, and a phenotypic switch in matrix-producing pro-fibrotic fibroblasts.
In contrast, inactivation of PU.1 disrupts the fibrotic network and enables re-programming of fibrotic fibroblasts into resting fibroblasts with regression of fibrosis in different organs. Targeting of PU.1 may thus represent a novel therapeutic approach for the treatment of a wide range of fibrotic diseases.
|
| |
|
| Overall design |
The 21 analyzed samples belong to 6 different groups with 3 to 4 biological replicates per group. Two of the groups consisted of control samples.
|
| |
|
| Contributor(s) |
Ramming A, Wohlfahrt T, Uebe S, Ekici AB |
| Citation(s) |
30700907 |
| |
| Submission date |
Nov 08, 2018 |
| Last update date |
Mar 27, 2019 |
| Contact name |
Steffen Uebe |
| E-mail(s) |
steffen.uebe@uk-erlangen.de
|
| Phone |
+49-9131-85-36103
|
| Organization name |
Uniklinikum Erlangen
|
| Department |
Humangenetisches Institut
|
| Street address |
Kussmaulallee 4
|
| City |
Erlangen |
| ZIP/Postal code |
91054 |
| Country |
Germany |
| |
|
| Platforms (1) |
| GPL16791 |
Illumina HiSeq 2500 (Homo sapiens) |
|
| Samples (21)
|
|
| Relations |
| BioProject |
PRJNA504646 |
| SRA |
SRP168244 |
Less...
More...